Costs of the management of hemophilia A with inhibitors in Spain

Autor: Santiago Bonanad, María Teresa Álvarez, Ramiro Núñez, José Luis Poveda, Beatriz Gil, Elena Ruíz-Beato, Ana Durán, Yoana Ivanova, Inés Pérez-Román, Almudena González-Domínguez

Publikováno v: Global & Regional Health Technology Assessment, Vol 8 (2021)

Introduction: Emicizumab is a first-in-class monoclonal antibody, recently authorized for the treatment of hemophilia A with inhibitors. This study aims to estimate the direct and indirect costs of the management of hemophilia A with inhibitors, in a

Externí odkaz: https://doaj.org/article/4175ad5d84ca44c7858d1b089c0f955b

Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series

Autor: Nina Haagenrud Schultz, Runar Lundblad, Pål Andre Holme

Publikováno v: Journal of Medical Case Reports, Vol 12, Iss 1, Pp 1-5 (2018)

Abstract Background The lack of an antidote against factor Xa inhibitors in case of major bleeding or need for urgent surgery is a concern to clinicians. Guidelines on managing major bleeding in patients under anticoagulation with a factor Xa inhibit

Externí odkaz: https://doaj.org/article/06579b78a9444673a6aca1dc17d9aecb

Acquired Haemophilia A. Which is the best therapeutic choice in older adults? Single center study of 4 cases

Autor: E. Mauro, E. Garlatti Costa, A. Zanier, M. Maset, A. Ermacora, M. Ghersetti, P. Casarin

Publikováno v: Reumatismo, Vol 71, Iss 1 (2019)

Acquired haemophilia A (AHA) is a rare bleeding disorder due to autoantibodies directed against coagulation factor VIII. The treatment is based on recombinant activated factor VII and activated prothrombin complex concentrate. However, mainly in olde

Externí odkaz: https://doaj.org/article/28d58df58f9f41139745f1cd49116431

Costs of the management of hemophilia A with inhibitors in Spain

Autor: Ana Durán, Ramiro Núñez, Inés Pérez-Román, Elena Ruiz-Beato, Yoana Ivanova, Santiago Bonanad, José Luis Poveda, Almudena González-Domínguez, M. T. Alvarez, Beatriz Gil

Publikováno v: Global & Regional Health Technology Assessment, Vol 8 (2021)
GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Introduction: Emicizumab is a first-in-class monoclonal antibody, recently authorized for the treatment of hemophilia A with inhibitors. This study aims to estimate the direct and indirect costs of the management of hemophilia A with inhibitors, in a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f54f4152b775a06ae080539530f54bd
https://doi.org/10.33393/grhta.2021.2234

Outcomes of activated prothrombin complex concentrate for direct Xa inhibitor bleeding

Autor: Nour Baalbaki, Maureen A. Smythe, Karissa Fritsch, Sean Mertz, John M. Koerber, Fatme Chehab, Anant Krishnan, Janet Hoffman

Publikováno v: Thrombosis research. 206

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93709df791179024e042320cb26afa57
https://pubmed.ncbi.nlm.nih.gov/34481221